Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epilepsy and mTORC1-Related Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DEPDC5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DEPDC5 Recombinant Protein High purity (>90%), Endotoxin <1EU/ug. Sequence Verified. Sf9/HEK293 expressed. |
View DEPDC5 Products |
| Gene Delivery | DEPDC5 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and expression rescue assays. |
View DEPDC5 Products |
| Benchmark Ab | Anti-DEPDC5 Recombinant Antibody Recombinant positive control for Western Blot and Immunoprecipitation. |
View DEPDC5 Products |
| Validator | DEPDC5 siRNA Set For knockdown verification and GATOR1-pathway phenocopying. |
View DEPDC5 Products |
| Related Target A | NPRL2 Essential GATOR1 complex subunit; co-regulates mTORC1 with DEPDC5. |
View NPRL2 Products |
| Related Target B | NPRL3 GATOR1 complex partner; critical for GTPase-activating protein activity. |
View NPRL3 Products |
| Related Target C | mTOR Downstream effector; hyperactivated upon DEPDC5 loss-of-function. |
View mTOR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GATOR1 Complex Reconstitution | Co-expression compatible DEPDC5, NPRL2, and NPRL3 proteins with verified purity and molecular weight. |
| Loss-of-Function Rescue Assays | High-titer Lentivirus for stable DEPDC5 reconstitution in patient-derived lymphoblastoid or neuronal cells. |
| Lack of Controls | Highly specific benchmark antibodies validated for endogenous DEPDC5 detection. |
| Off-Target Pathway Verification | Validated siRNA pools to confirm mTORC1-dependence versus alternative signaling cascades. |
Live DEPDC5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DEPDC5-targeted therapeutics is intensifying, with major players shifting focus from traditional small molecule mTOR inhibitors (rapalogs) to genetic medicines and GATOR1-complex restorers. As first-generation systemic mTOR inhibitors face blood-brain barrier (BBB) and systemic toxicity limitations in focal epilepsy, the next wave of R&D is targeting localized gene therapies, mRNA-mediated restoration, and small molecules that selectively stabilize the GATOR1 complex to downregulate hyperactive mTORC1 in mutated neurons.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV / mRNA) | Academic Medical Centers, Biotech Startups | Focal Epilepsy, Cortical Dysplasia | Functional rescue assays (Need high-titer Lentivirus & expression vectors) |
| Small Molecule (GATOR1 Stabilizers) | CNS-focused Pharmaceutical Companies | DEPDC5-mutated Epilepsy, mTORopathies | In vitro binding & complex assembly assays (Need pure DEPDC5/NPRL2/NPRL3 proteins) |
| mTORC1 Inhibitors (CNS-penetrant) | Neuro-therapeutics Developers | Seizure control, TSC-related Epilepsy | Selectivity and pathway readout assays (Need downstream phosphorylated target controls) |